Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models

Neurobiology of Disease

Volumn 79, Issue , 2015, Pages 70-80

  Li, Wei ^a,b   Silva, Henrique B ^c   Real, Joana ^c   Wang, Yu Mei ^a   Rial, Daniel ^c   Li, Ping ^a,b   Payen, Marie Pierce ^a   Zhou, Yuanguo ^b   Muller, Christa E ^a   Tomé, Angelo R ^c   Cunha, Rodrigo A ^c,d   Chen, Jiang Fan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Adenosine A2A receptor; Cognition; Huntington's disease; Long term depression; R6 2 mice; Working memory

Indexed keywords

ADENOSINE A2A RECEPTOR; ISTRADEFYLLINE; PHOSPHOPROTEIN DARPP 32; ADENOSINE A2 RECEPTOR ANTAGONIST; PURINE DERIVATIVE; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BINDING KINETICS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; GAIN OF FUNCTION MUTATION; GENE INACTIVATION; HUNTINGTON CHOREA; LONG TERM POTENTIATION; MALE; MOTOR COORDINATION; MOUSE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REFERENCE MEMORY; SURVIVAL TIME; UBIQUITINATION; WORKING MEMORY; ANIMAL; ASTROCYTE; BRAIN CORTEX; C57BL MOUSE; CELL INCLUSION; COGNITION DISORDERS; CORPUS STRIATUM; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLIOSIS; KNOCKOUT MOUSE; LONG TERM DEPRESSION; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SHORT TERM MEMORY; TRANSGENIC MOUSE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ASTROCYTES; CEREBRAL CORTEX; COGNITION DISORDERS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLIOSIS; HUNTINGTON DISEASE; INCLUSION BODIES; LONG-TERM SYNAPTIC DEPRESSION; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PURINES; RECEPTOR, ADENOSINE A2A; UBIQUITIN;

EID: 84929459097     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.030     Document Type: Article

References (96)

1. Albasanz J.L., Perez S., Barrachina M., Ferrer I., Martín M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol. 2008, 18:211-219.
2. Anderson W.W., Collingridge G.L. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 2001, 108:71-83.
3. 2A receptor functions. J. Neurosci. 2013, 33:11390-11399.
4. Bannon N.M., Zhang P., Ilin V., Chistiakova M., Volgushev M. Modulation of synaptic transmission by adenosine in layer 2/3 of the rat visual cortex in vitro. Neuroscience 2014, 260:171-184.
5. 2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. Mol. Psychiatry 2013, 18:320-331.
6. Bradford J., Shin J.Y., Roberts M., Wang C.E., Li X.J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:22480-22485.
7. Brooks S.P., Betteridge H., Trueman R.C., Jones L., Dunnett S.B. Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease. Brain Res. Bull. 2006, 69:452-457.
8. Brooks S.P., Janghra N., Higgs G.V., Bayram-Weston Z., Heuer A., Jones L., Dunnett S.B. Selective cognitive impairment in the YAC128 Huntington's disease mouse. Brain Res. Bull. 2012, 88:121-129.
9. 2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 2009, 29:14741-14751.
10. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
11. Cepeda C., Wu N., André V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
12. Cepeda C., Cummings D.M., Hickey M.A., Kleiman-Weiner M., Chen J.Y., Watson J.B., Levine M.S. Rescuing the corticostriatal synaptic disconnection in the R6/2 mouse model of Huntington's disease: exercise, adenosine receptors and ampakines. PLoS Curr. 2010, 2:RRN1182.
13. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 1999, 19:9192-9200.
14. 2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Hum. Mol. Genet. 2009, 18:2929-2942.
15. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 2005, 93:310-320.
16. 2A receptor heteromers. J. Neurosci. 2006, 26:2080-2087.
17. 2A receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. J. Neurochem. 2010, 112:453-462.
18. Cummings D.M., Milnerwood A.J., Dallérac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:2856-2868.
19. 2A receptor-mediated facilitation of plasticity. Neurochem. Int. 2008, 52:65-72.
20. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010, 20(Suppl. 1):S95-S116.
21. 2A receptor blockade prevents memory dysfunction caused by β-amyloid peptides but not by scopolamine or MK-801. Exp. Neurol. 2008, 210:776-781.
22. Dalbem A., Silveira C.V., Pedroso M.F., Breda R.V., Werne Baes C.V., Bartmann A.P., da Costa J.C. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res. 2005, 1047:148-158.
23. 2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 2001, 107:455-464.
24. 2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 2007, 203:241-245.
25. Dallerac G.M., Vatsavayai S.C., Cummings D.M., Milnerwood A.J., Peddie C.J., Evans K.A., Walters S.W., Rezaie P., Hirst M.C., Murphy K.P. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation. Neurodegener. Dis. 2011, 8:230-239.
26. Deng Y.P., Wong T., Bricker-Anthony C., Deng B., Reiner A. Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol. Dis. 2013, 60:89-107.
27. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
28. 2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 2007, 28:197-205.
29. Duarte J.M.N., Agostinho P.M., Carvalho R.A., Cunha R.A. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One 2012, 7:e21899.
30. Duff K., Paulsen J., Mills J., Beglinger L.J., Moser D.J., Smith M.M., Langbehn D., Stout J., Queller S., Harrington D.L., PREDICT-HD Investigators and Coordinators of the Huntington Study Group Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010, 75:500-507.
31. 2A receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine. Neuropharmacology 2008, 55:35-40.
32. 2A receptor deficient mice are partially resistant to limbic seizures. Naunyn Schmiedeberg's Arch. Pharmacol. 2009, 380:223-232.
33. 2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. J. Alzheimers Dis. 2013, 34:509-518.
34. Ferré S., Lluís C., Justinova Z., Quiroz C., Orru M., Navarro G., Canela E.I., Franco R., Goldberg S.R. Adenosine-cannabinoid receptor interactions, implications for striatal function. Br. J. Pharmacol. 2010, 160:443-453.
35. 2A receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
36. Gerdeman G.L., Ronesi J., Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 2002, 5:446-451.
37. Gil J.M., Rego A.C. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res. Rev. 2009, 59:410-431.
38. Giralt A., Puigdellívol M., Carretón O., Paoletti P., Valero J., Parra-Damas A., Saura C.A., Alberch J., Ginés S. Cognitive dysfunction in Huntington's disease: humans, mouse models and molecular mechanisms. J. Huntingtons Dis. 2012, 1:155-173.
39. Goldman-Rakic P.S. Regional and cellular fractionation of working memory. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13473-13480.
40. 2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J. Org. Chem. 2004, 69:3308-3318.
41. Höhn S., Dallérac G., Faure A., Urbach Y.K., Nguyen H.P., Riess O., von Hörsten S., Le Blanc P., Desvignes N., El Massioui N., Brown B.L., Doyère V. Behavioral and in vivo electrophysiological evidence for presymptomatic alteration of prefrontostriatal processing in the transgenic rat model for Huntington disease. J. Neurosci. 2011, 31:8986-8997.
42. Hong S.L., Cossyleon D., Hussain W.A., Walker L.J., Barton S.J., Rebec G.V. Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington's disease. PLoS One 2012, 7:e47026.
43. Huang N.K., Lin J.H., Lin J.T., Lin C.I., Liu E.M., Lin C.J., Chen W.P., Shen Y.C., Chen H.M., Chen J.B., Lai H.L., Yang C.W., Chiang M.C., Wu Y.S., Chang C., Chen J.F., Fang J.M., Lin Y.L., Chern Y. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 2011, 6:e20934.
44. Joshi P.R., Wu N.P., André V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009, 29:2414-2427.
45. 2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl) 2013, 230:345-352.
46. Kheirbek M.A., Britt J.P., Beeler J.A., Ishikawa Y., McGehee D.S., Zhuang X. Adenylyl cyclase type 5 contributes to corticostriatal plasticity and striatum-dependent learning. J. Neurosci. 2009, 29:12115-12124.
47. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 2001, 86:2667-2677.
48. Kung V.W., Hassam R., Morton A.J., Jones S. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 2007, 146:1571-1580.
49. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., Ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121:1329-1341.
50. Li J.Y., Plomann M., Brundin P. Huntington's disease: a synaptopathy?. Trends Mol. Med. 2003, 9:414-420.
51. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
52. 2A receptor knockout mice. Br. J. Pharmacol. 2004, 141:1006-1014.
53. Lovinger D.M. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 2010, 58:951-961.
54. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
55. 1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J. Neurochem. 2011, 116:273-280.
56. 2A receptors control the amyloid-β peptide-induced decrease of glutamate uptake. J. Alzheimers Dis. 2012, 31:555-567.
57. Mazarakis N.K., Cybulska-Klosowicz A., Grote H., Pang T., Van Dellen A., Kossut M., Blakemore C., Hannan A.J. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. J. Neurosci. 2005, 25:3059-3066.
58. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 2002, 23:32-39.
59. 2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2011, 41:570-576.
60. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-523.
61. Milnerwood A.J., Cummings D.M., Dallérac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1690-1703.
62. 2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J. Neuropathol. Exp. Neurol. 2007, 66:363-371.
63. Nishi A., Watanabe Y., Higashi H., Tanaka M., Nairn A.C., Greengard P. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1199-1204.
64. Pandolfo P., Machado N.J., Köfalvi A., Takahashi R.N., Cunha R.A. Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur. Neuropsychopharmacol. 2013, 23:317-328.
65. Papp K.V., Kaplan R.F., Snyder P.J. Biological markers of cognition in prodromal Huntington's disease: a review. Brain Cogn. 2011, 77:280-291.
66. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
67. 2A receptors in Huntington's disease. Prog. Neurobiol. 2007, 81:331-348.
68. 2A receptors. Neurobiol. Aging 2005, 26:957-964.
69. 2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 2009, 9:1321-1344.
70. 2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J. Neurophysiol. 2003, 90:1295-1303.
71. 2A receptors in the hippocampus and striatum of the rat. Neuroscience 2005, 132:893-903.
72. 2A receptors in the rat cerebral cortex. Epilepsia 2005, 46(Suppl. 5):159-165.
73. 2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008, 57:121-134.
74. 2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J. Neurochem. 2011, 117:100-111.
75. 2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 2005, 92:433-441.
76. Rodrigues R.J., Canas P.M., Lopes L.V., Oliveira C.R., Cunha R.A. Modification of adenosine modulation of acetylcholine release in the hippocampus of aged rats. Neurobiol. Aging 2008, 29:1597-1601.
77. 2A receptors in brain: morphological substrates for integration of striatal function. Neurology 2003, 61:S12-S18.
78. 2A receptors and basal ganglia physiology. Prog. Neurobiol. 2007, 83:277-292.
79. 2A receptor activation: implications for neuroprotection. Br. J. Pharmacol. 2009, 158:15-22.
80. Selkoe D.J., Salazar F.J., Abraham C., Kosik K.S. Huntington's disease: changes in striatal proteins reflect astrocytic gliosis. Brain Res. 1982, 245:117-125.
81. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 2004, 56:319-328.
82. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
83. 2A receptors in striatal glutamatergic terminals and GABAergic neurons oppositely modulate psychostimulant action and DARPP-32 phosphorylation. PLoS One 2013, 8:e80902.
84. Simonin C., Duru C., Salleron J., Hincker P., Charles P., Delval A., Youssov K., Burnouf S., Azulay J.P., Verny C., Scherer C., Tranchant C., Goizet C., Debruxelles S., Defebvre L., Sablonnière B., Romon-Rousseaux M., Buée L., Destée A., Godefroy O., Dürr A., Landwehrmeyer B., REGISTRY Study of the European Huntington's Disease Network, Bachoud-Levi A.C., Richard F., Blum D., Krystkowiak P., Huntington French Speaking Network Association between caffeine intake and age at onset in Huntington's disease. Neurobiol. Dis. 2013, 58:179-182.
85. Stout J.C., Paulsen J.S., Queller S., Solomon A.C., Whitlock K.B., Campbell J.C., Carlozzi N., Duff K., Beglinger L.J., Langbehn D.R., Johnson S.A., Biglan K.M., Aylward E.H. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011, 25:1-14.
86. 2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 2006, 23:44-53.
87. 2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-d-aspartate effects. J. Neurochem. 2005, 95:1188-1200.
88. 2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 2007, 53:783-789.
89. Trueman R.C., Brooks S.P., Jones L., Dunnett S.B. Rule learning, visuospatial function and motor performance in the Hdh(Q92) knock-in mouse model of Huntington's disease. Behav. Brain Res. 2009, 203:215-222.
90. 2A receptors contributes to cognitive dysfunction in Huntington's disease. Neurobiol. Dis. 2014, 74:41-57.
91. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 2005, 25:4169-4180.
92. 2A receptors in striatal neurons enhances working memory and reversal learning. Learn. Mem. 2011, 18:459-474.
93. 2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology 2004, 46:994-1007.
94. 2A adenosine receptors in the striatum selectively impairs habit formation. J. Neurosci. 2009, 29:15100-15103.
95. 2A receptors. Brain Res. 2009, 1303:74-83.
96. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.